JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation | HTML
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram
Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates | Journal for ImmunoTherapy of Cancer
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
REVEL Trial Progression-Free Survival for mNSCLC | CYRAMZA® (ramucirumab)
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Kaplan-Meier curve of median progression-free survival (PFS) and... | Download Scientific Diagram
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
NEJM on Twitter: "KEYNOTE-836: In advanced cervical cancer, median PFS was 10.4 months with pembrolizumab and 6 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively. #ESMO21 https://t.co/sZd6SFiGKd
Progression-Free Survival (PFS) | REVLIMID® (lenalidomide) + rituximab
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
